Результаты поиска

Inflammatory markers from routine blood tests predict survival in multiple myeloma: a Systematic Review and meta-analysis.

BACKGROUND: Multiple myeloma (MM) is an incurable hematologic malignancy marked by abnormal plasma cell proliferation. Inflammatory indices derived from routine blood tests-such as neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), red cell distribution width (RDW), RDW-to-platelet ratio (RPR), and hemoglobin-to-RDW ratio (HRR)-have shown prognostic value across cancers. This meta-analysis aimed to evaluate their prognostic significance in MM. METHODS: Following PRISMA guidelines, a systematic search of PubMed, Embase, and Web of Scie…

Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.

Multiple myeloma (MM) cells induce relevant angiogenic effects within the human bone marrow milieu (huBMM) by the aberrant expression of angiogenic factors. Hypoxia triggers angiogenic events within the huBMM and the transcription factor hypoxia-inducible factor-1α (HIF-1α) is over-expressed by MM cells. Since synthetic miR-199a-5p mimics negatively regulates HIF-1α, we here investigated a miRNA-based therapeutic strategy against hypoxic MM cells. We indeed found that enforced expression of miR-199a-5p led to down-modulated expression of HIF-1α as well as of other pro-angiogenic factors such a…

Hypophosphatemia in cancer patients.

Dysregulation of phosphorus homeostasis resulting in hypophosphatemia is common in cancer patients and can result in serious complications and impact outcomes. Several factors, including critical illness, nutritional status, cancer type and therapy, influence the development of hypophosphatemia. Hypophosphatemia can develop as a result of phosphaturic mesenchymal tumors or as a paraneoplastic phenomenon. The clinical presentation for hypophosphatemia varies depending on the duration and severity of the hypophosphatemia and affects several organ systems. Among other serious effects, hypophospha

Совпадение в полном тексте источника
… Similarly, spurious hypophosphatemia should be in the differential of multiple myeloma (MM) and other paraproteinemias due to paraprotein’s interference with the phosphate assay [ 49 ]. … Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma . Blood 2004 ; 104 : 40 – 42 15010372 10.1182/blood-2003-10-3400 102 Dash T , Parker MG , Lafayette RA. Profound hypophosphatemia and isolated hyperphosphaturia in two cases of multiple myeloma . …

Целевое воздействие на ось MARCH5-MFN2 для усиления фузии митохондрий и чувствительности клеток множественной миеломы к венетоклаксу.

ОБЗОР: Накопленные данные указывают на то, что события физиологического деления и слияния митохондрий нарушены в раке из-за нарушения функции их ключевых регуляторов. В данном исследовании мы изучали функциональную роль E3-убиквитин-лигазы Мембранный ассоциированный Ринг-Ч-Тип Фингер 5 (MARCH5) в регуляции роста клеток, метаболической переработки и устойчивости к лекарствам в мультиплексной миеломе (ММ) через отрицательную регуляцию драйвера слияния митохондрий митофузина 2 (MFN2). МЕТОДЫ: Вiability клеток и апоптоз оценивались в линиях клеток ММ или в кокультуре с стромальными клетками с исп

Совпадение в аннотации оригинала
BACKGROUND: Accumulating evidence suggests that mitochondrial fission and fusion events are imbalanced in cancer due to defective activity o … CH-Type Finger 5 (MARCH5) in regulating cell growth, metabolic reprogramming and drug resistance in multiple myeloma (MM) through the negative regulation of the mitochondrial fusion driver mitofusin 2 (MFN2). METHODS: Cell viability and apoptosis were evaluated in MM cell lines or in co-culture with stromal cells using the CellTiter-Glo® Cell Viability Assay and …

Bridging the Gap in Secondary Antibody Deficiencies: Current Evidence and Unmet Needs in Diagnosis and Management with Immunoglobulin Replacement.

Secondary antibody deficiency (SAD) represents a substantial yet under-recognised global healthcare burden. It is more prevalent than primary antibody deficiency, but frequently under-diagnosed and variably managed worldwide. Prompt diagnosis is often hindered by insufficient awareness among clinicians, lack of global consensus on screening/monitoring for SAD among at-risk patients, inadequate clinical immunology services and lack of standardised referral pathways/protocols. Management practices vary widely, with little international agreement, particularly regarding threshold to initiate immu

Совпадение в полном тексте источника
… global burden of multiple myeloma and 29 years forecast. … Wonnaparhown A Hilal T Squire J Freeman C Fonseca R IgG replacement in multiple myeloma Blood Cancer J 2024 14 1 124 10.1038/s41408-024-01107-6 39054331 PMC11272770 Wonnaparhown A, Hilal T, Squire J, Freeman C, Fonseca R (2024) IgG replacement in multiple myeloma. …

Animal Models in Rheumatoid Arthritis: Is There a Correlation Between Autoantibodies in Human Pathology and Animal Models?

RA is a chronic autoimmune disease characterized by synovial inflammation and joint damage, driven by autoantibodies such as ACPA, anti-CarP and RF. These autoantibodies, influenced by genetic and environmental factors, play a crucial role in RA pathogenesis through post-translational modifications like citrullination, carbamylation, and acetylation. The early detection of ACPA provides a potential window for intervention, while anti-CarP antibodies correlate with severe disease progression and RF aids in diagnosis. Translating these findings from human pathology to animal models presents sign

Совпадение в полном тексте источника
… Also, RF is present in about 25–30% cases of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma or multiple myeloma [ 28 ]. …

Application of dendritic cell extracellular vesicles as a valid nanoparticle platform for cancer therapies: a narrative review.

The prevalence of cancers has actually increased during the last few decades, affecting almost all human societies. Despite progress in therapeutic protocols, cancer is still the main cause of global human mortality. Although the advancement of modern immunotherapeutic approaches can increase the survival rate of cancer patients, new modalities are essential for improved therapeutic outcomes. Extracellular vesicles (EVs) are nanosized particles and are used for cell-free approaches instead of direct whole cell-based administration. It has been thought that EVs can reduce the risks and side eff

Совпадение в полном тексте источника
… Myeloma COMPLETED Lymphoma, Multiple Myeloma, and Plasma Cell Neoplasm INTERVENTIONAL NCT01348256 Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma UNKNOWN Colorectal Carcinoma Hepatic Metastasis DRUG: Dendritic cells vaccine NCT00940004 Toll-like Receptor … Myeloma COMPLETED Multiple Myeloma BIOLOGICAL: Dendritic Cell Tumor Fusion Vaccine NCT00345293 Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer COMPLETED Prostate Cancer BIOLOGICAL: autologous dendritic cell vaccine (DC/PC3) NCT03185429 TSA-DC Vaccine in Treating Patients with Gastrointestinal …

Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma.

Daratumumab-lenalidomide (DR) combination therapy improves multiple myeloma (MM) outcomes, yet some patients respond poorly. We examined 21 DR pre-treatment samples from the IFM2017-03 phase 3 trial using single-cell and bulk multiomics approaches to identify determinants of response. Analysis of the bone marrow environment revealed a coordinated inflammatory state across immune and myeloma cells associated with DR resistance. We identified upregulated NF-κB signaling genes in monocytes of non-responders, alongside increased proinflammatory ISG + T cells and attenuated NK cell CD16 expression,…

Strategies for promoting exercise adherence within a cancer exercise recovery program: a qualitative case study.

BACKGROUND: Physical activity (PA) plays an important role in physical health and well-being for cancer survivors. However, cancer survivors demonstrate low adherence to cancer PA guidelines. Research is needed to understand how to optimize delivery of cancer PA programs to enhance participation and adherence. In this study, we conducted an instrumental qualitative case study of a clinical cancer exercise recovery program (CERP) demonstrating high adherence (over 90% session completion), with the goal of understanding implementation strategies that patients link to higher program adherence. ME

Совпадение в полном тексте источника
… Table 1 Demographic characteristics of CERP patients Pseudonym | Age | Race/ethnicity | Gender | Cancer Type | Format of Exercise Participation Aaron | 61 | White/Non-Hispanic | Male | Multiple myeloma | Virtual Barbara | 55 | White/Non-Hispanic | Female | Breast cancer | In-person Caroline | 55 | White …

Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy.

Patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are prone to present with antibody production deficits associated with recurrent or severe bacterial infections that might benefit from human immunoglobulin (Ig) (IVIg/SCIg) replacement therapy. However, the original IVIg trial data were done before modern therapies were available, and the current indications do not take into account the shift in the immune situation of current treatment combinations and changes in the spectrum of infections. Besides, patients affected by other B cell malignancies present with similar i…

Влияние жизненных поступков, способствующих укреплению здоровья, на микробиоту у выживших жертв гематологического рака: обзор скопирования.

Целью этого аналитического обзора является изучение взаимосвязи между поведением, способствующим здоровому образу жизни, и микробиотой кишечника у выживших жертв гематологического рака, включая лейкемию, лимфому и множественную миелому. С учетом растущего числа таких случаев и связанных с этим проблем с лечением понимание того, как факторы образа жизни влияют на состояние здоровья, может дать представление о том, как улучшиться состояние выживших жертв. МЕТОДЫ: Мы провели всеобъемлющий поиск по нескольким базам данных, включая PubMed/Medline, CINAHL и Scopus, вслед за предпочтительными элемент

Совпадение в аннотации оригинала
PURPOSE: This scoping review aims to explore the relationship between health-promoting lifestyle behaviors and gut microbiota in survivors of hematological cancers, including leukemia, lymphoma, and multiple myeloma. Given the rising incidence of these malignancies and the associated treatment challenges, understanding how lifestyle factors influence gut hea…

Interleukins in cancer: from biology to therapy.

Interleukins and associated cytokines serve as the means of communication for innate and adaptive immune cells as well as non-immune cells and tissues. Thus, interleukins have a critical role in cancer development, progression and control. Interleukins can nurture an environment enabling and favouring cancer growth while simultaneously being essential for a productive tumour-directed immune response. These properties of interleukins can be exploited to improve immunotherapies to promote effectiveness as well as to limit side effects. This Review aims to unravel some of these complex interactio

Совпадение в полном тексте источника
… IL-17 can accelerate the progression of multiple myeloma 174 , and another study showed that IL-17 neutralization indeed can lead to a reduction in multiple myeloma growth 175 . … A clinical trial that started in 2017 ( NCT03111992 (ref. 176 )) is now exploring the efficacy of the anti-IL-17A antibody CJM112 in multiple myeloma. …

A life span perspective on competencies for a healthy, physically active lifestyle: Findings of a data pooling initiative with over 7000 individuals.

Individuals are recommended to lead active lifestyles throughout the life course. The model of physical activity-related health competence (PAHCO) adopts a competence approach by integrating physical, cognitive, and motivational determinants for health-enhancing PA (movement competence, control competence, self-regulation competence). Drawing on a comprehensive dataset pooling, the goal of the present study was to model the idiosyncratic courses of 10 PAHCO indicators over the life span. We identified studies that empirically operationalized PAHCO, combining data of 7134 individuals (age range

Совпадение в полном тексте источника
… myeloma (MM; n = 98); (b) smoldering multiple myeloma (SMM; n = 28) 18 | Persons with spondyloarthritis | Baseline values of a long‐term study (routine data) at the university hospital Erlangen | FAU Erlangen‐Nürnberg (not published) | 106 | 51.25 ± 12.61 [range 22–84] | 54.4% male, 45.6% female | X … Myeloma: A Latent Profile Analysis .” …

Hemato-Oncology Care During and After the COVID-19 Pandemic: Changes in Treatment Pathways, Patient Flow, and Durable Organizational Adaptations.

The COVID-19 pandemic disrupted cancer care at every level of the clinical pathway, but its effect on hemato-oncology was distinctive because patients with hematologic malignancies often require urgent diagnosis, frequent hospital visits, transfusion support, intensive therapy, transplantation, cellular therapy, and infection-sensitive follow-up. This narrative review examines the pandemic as a disruption of hemato-oncology care delivery rather than only as a source of excess infection-related morbidity. It synthesizes evidence on diagnostic access, patient flow, treatment prioritization, infe

Совпадение в полном тексте источника
… Search terms were combined using disease-, care-delivery-, and pandemic-related concepts, including “COVID-19”, “SARS-CoV-2”, “hematologic malignancies”, “haematological malignancies”, “hemato-oncology”, “leukemia”, “lymphoma”, “multiple myeloma”, “patient flow”, “cancer care disruption”, “telemedicine … The review focuses on adult patients with HMs, including acute leukemias, aggressive and indolent lymphomas, chronic lymphocytic leukemia (CLL), multiple myeloma and related plasma cell disorders, myeloid neoplasms, patients undergoing HCT, and patients receiving cellular or immune-based therapies, including …

Leiomyosarcomas of the Great Saphenous Vein: Diagnostic and Therapeutic Strategies to Prevent Unplanned Excisions and Improve Oncologic, Functional, and Psychological Outcomes.

Background/objectivesThere are very few publications on unplanned excisions of great saphenous vein leiomyosarcomas (GSV-LMS), and their impact on the prognosis of the disease is not well known. The objective of this study is to present a series of nine new leiomyosarcomas of the great saphena vein (LMS-GSV) cases, with the aim of increasing diagnostic awareness and proposing guidelines for therapeutic management.MethodsThis is a prospective single-centre study of a series of nine GSV-LMS in thigh (stage IIIA AJCC), knee and proximal leg (IB, 1 II and 3 IIIA), and ankle (2 IIIB and 1 II). Eigh

Совпадение в полном тексте источника
… SMM = smoldering multiple myeloma. R = right. L = left. L = leiomioma. LMS = leiomyosarcoma. HE = haemangioendothelioma. DMFS = dermatofibrosarcoma. UE = unplanned excision. IM = intralesional margin. UM = unknown margin. …

Rice Bran Arabinoxylan Compound and Quality of Life (RBAC-QoL) of Cancer Patients: An Interim Analysis of the RBAC-QoL Study.

Background The effect of rice bran arabinoxylan compound (RBAC), a plant-based immunomodulator, on the quality of life (QoL) in cancer patients and underlying physiological pathways remains unclear. Trial design The RBAC-QoL study, a double-blind, randomised, controlled pilot feasibility study, aimed to determine RBAC's effects on QoL and the associated action mechanisms. Primary outcomes were the EORTC QLQ-C30 functional, symptom, and global QoL scores with inflammatory, nutritional, and cytokine parameters as secondary and exploratory outcomes. Methods Participants were adults diagnosed with

Совпадение в полном тексте источника
… The potential effects of RBAC on cancer patients’ neutrophil count were previously reported by Golombick et al. [ 21 ] in a single-arm before and after study in patients with monoclonal gammopathy of undetermined significance (MGUS)/smouldering multiple myeloma (SMM). … Addition of rice bran arabinoxylan to curcumin therapy may be of benefit to patients with early-stage B-cell lymphoid malignancies (monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or stage 0/1 chronic lymphocytic leukemia): a preliminary clinical study. …

ЦАРТ клетки в качестве новой терапевтической стратегии для множественных склерозов и других нейроиммунных расстройств.

В качестве трансформационного подхода к лечению множественных склерозов (MS) и других нейроиммунных расстройств, таких, как расстройства спектра нейромиелита (NMOSD), миелин олигодендроцита гликпротеина, связанных с антителами (MOGAD), и миастения гравис (MG), наряду с рядом других редких нейроиммунологических заболеваний, которые в настоящее время оцениваются в исследованиях, посвященных сочувствию или ранней фазе. Отчасти эти условия обусловлены автоматически реактивными клетками B, вызывающими хроническое воспаление и прогрессивное повреждение тканей. Несмотря на то, что нынешняя иммунодуля

Совпадение в полном тексте источника
… More recently, BCMA-directed therapies, idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti), have been approved for relapsed or refractory multiple myeloma [ 40 ]. … Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16. 82. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. …

Advances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies.

The role of immunotherapy in oncohematology is well established. Monoclonal antibodies have undergone substantial development in recent years, targeting a wide range of molecules (including surface antigens, immune checkpoints, and cytokines) and have demonstrated clinical utility across various hematologic malignancies, including leukemias, lymphomas, and myelomas. The emergence of advanced therapy medicinal products (ATMPs), particularly chimeric antigen receptor (CAR) T cells, has provided an additional and promising therapeutic option. This rapidly evolving field continues to expand therap

Совпадение в полном тексте источника
… myeloma (MM). … Daratumumab is now incorporated into international clinical practice guidelines for multiple myeloma, including frontline treatment regimens. …

Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology.

Bispecific antibodies (bsAbs) have become an integral component of the therapeutic research strategy to treat cancer. In addition to clinically validated immune cell re-targeting, bsAbs are being designed for tumor targeting and as dual immune modulators. Explorative preclinical and emerging clinical data indicate potential for enhanced efficacy and reduced systemic toxicity. However, bsAbs are a complex modality with challenges to overcome in early clinical trials, including selection of relevant starting doses using a minimal anticipated biological effect level approach, and predicting effic

Совпадение в полном тексте источника
… Oncol. 12 , S49 – S55 ( 2001 ). 10.1093/annonc/12.suppl_1.s49 11521722 52 Sanchez , E. et al Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival . Br. J. … Haematol. 158 , 727 – 738 ( 2012 ). 22804669 10.1111/j.1365-2141.2012.09241.x 53 Ghermezi , M. et al Serum B‐cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients . …

Первичное лечение нескольких пациентов, страдающих миэломой: оптимизация лечения пациентов в регионе Залива.

Варианты лечения недавно диагностированной миеломы (NDMM) значительно расширились за последние годы two десятилетиями, что привело к заметному улучшению показателей ответов и средней продолжительности жизни. Применительно к пациентам, имеющим на это право, аутологическая трансплантация стволовых клеток играет центральную роль в общей стратегии лечения, включающей индукцию, трансплантацию, консолидацию и техническое обслуживание. В этой статье мы почерпнули из нашего собственного коллективного клинического опыта лечения пациентов с NDMM в регионе Залива, чтобы обсудить стратегии лечения как име

Совпадение в аннотации оригинала
Treatment options for newly diagnosed multiple myeloma (NDMM) have expanded dramatically over the last two decades, resulting in remarkable improvements in response rates and median survival times. In eligible patients, autologous stem cell transplant plays the central role of an overall treatment strategy comprising induction, transplantation, consolidation…